Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon

Not Applicable

Recruiting

• Conditions: Macular Edema (ME); Non Infectious Uveitis
• Interventions: Drug: Suprachoroidal triamcinolone acetonide injection

• Registration Number: NCT07145008
• Lead Sponsor: Baghdad college of medicine

Brief Summary

The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).

The main questions it aims to answer are:

Does vision improve on the eye chart after the injection?

Does the injection lower retinal swelling (reduction in thickness) within 3 months?

Participants will:

Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).

Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.

Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.

Contact the clinic if they notice pain, redness, new floaters, or worsening vision.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-09-01
• Primary Completion: 2025-06-01
• Status Verified: 2025-08
• Study First Submitted: 2025-08-21
• Study First Submitted QC: 2025-08-21
• Last Update Submitted: 2025-08-21
• Study First Posted: 2025-08-28
• Last Update Posted: 2025-08-28
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Non-infectious uveitis complicated with macular edema
• Uveitic macular edema of less than four months' duration
• Macular edema persisted despite lack of intra-ocular inflammation
• No response to posterior sub-Tenon triamcinolone acetonide injections

Exclusion Criteria

• Those with epiretinal membrane-associated macular edema
• Below 18 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Suprachoroidal Triamcinolone treatment arm	Suprachoroidal triamcinolone acetonide injection	-

Primary Outcome Measures

Name	Time	Method
Visual acuity improvement	3 months	visual acuity improvement was defined as a gain of two or more lines in visual acuity or a reduction in logMAR values

Secondary Outcome Measures

Name	Time	Method
Central Macular Thickness	3 Months	A reduction in central macular thickness (CMT) exceeding 20%.

Trial Locations

Locations (1)

Ibn Al-Haitham Eye Teaching Hospital; 🇮🇶 Baghdad, Iraq